Martin Friedlander, MD, PhD, discusses phase 3 macular telangiectasia findings, highlighting the potential for a decade-long ...

According to the company, the suffix “-mod” in urcosimod denotes its classification as a modulator of key inflammatory and ...

The rationale for the study was anecdotal reports of the effects of breast milk used by mothers to treat blocked tear ducts, ...

QLS‑111 is a novel topical formulation using Qlaris Bio’s ATP-sensitive potassium channel modulator platform. QLS-111 lowers ...

The 36-week trial was a randomized, double-masked, parallel-group, active-controlled, multicenter evaluating CLS-AX (axitinib ...

Nathan Congdon, MD, highlights a recent study showing how virtual mentor-mentee relationships through Orbis' free ...

Ooms' poster at the Association of University Professors of Ophthalmology annual meeting highlighted a study on gray area ...

M. Roy Wilson, presented the Shaffer-Hetherington-Hoskins Lecture at the Glaucoma 360 meeting held in San Francisco, ...

PRISM evaluates 4D-150, a potential backbone therapy designed to provide multi-year sustained delivery of anti-VEGF ...

The pandemic caused an overall decrease in the rates of the 10 most common ophthalmic procedures performed in 2020 when ...

Regeneron Pharmaceuticals has announced results from the phase 3 QUASAR trial and its extension study of the phase 3 PULSAR ...

Ophthalmology Times spoke with Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis about how her ...